Document is current
Any future updates will be listed below
-
Authors
Dobrovolsky, A. P.
Gedzun, V. R.
Bogin, V. I.
Ma, D.
Ichim, T. E.
Sukhanova, Iu. A.
Malyshev, A. V.
Dubynin, V. A.
-
Funding
Funding for this research was provided by:
Russian Foundation for Basic Research (19-015-00345)
- License Information
-
More Information
Article History
Received: 24 March 2019
Accepted: 27 November 2019
First Online: 3 December 2019
Ethics approval and consent to participate
: All efforts were made to minimize the number of animals used. All protocols and procedures were conducted in accordance with Moscow State University’s Committee on Biomedical Research Ethics.
: Not applicable.
: Dr. Dobrovolsky is the co-founder of Nobilis Therapeutics, Inc., a company that is developing treatments for psychiatric disorders using noble gas xenon. Dr. Bogin is the co-founder and CEO of Nobilis Therapeutics, Inc., a company that is developing treatments for psychiatric disorders using noble gas xenon. Dr. Ma is the member of the scientific advisory board of Nobilis Therapeutics.
